Ajay Israni is a Nephrology physician. OpenAlex indexes 410 publications with 24,603 citations (h-index 80); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Nephrology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1005 Harborside Dr.
Fl 6
Galveston, TX 77555
Telephone
409-772-0750Provider last certified this registry record 18 Mar 2026.
Clinical trials
- Microbiome and Immunosuppression: The Mission Study
Sponsor: The University of Texas Medical Branch, Galveston
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20256 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
48.5%Beta blocker11.8%Carvedilol71%Metoprolol Succinate29%Part D<11 patientsStatin9.9%Atorvastatin Calcium100%Part D≥18 patients+ 6 more classes in this area
Metabolism & gastrointestinal
35.4%Corticosteroid15.2%Prednisone100%Part D≥23 patientsProton pump inhibitor9.9%Omeprazole53%Pantoprazole Sodium48%Part D<11 patients+ 2 more classes in this area
Hormonal (systemic)
6.6%Calcium-sensing Receptor Agonist6.6%Cinacalcet Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2024–2025 per NIH RePORTER. The latest:
- New Patient-centered Metric for Transplant Center Report Cards
University of Texas Med Br Galveston
FY2025$387,869R01HS028829 - Gut Microbiota and Effect on Immune Suppressants in Transplantation
University of Texas Med Br Galveston
FY2024$400,917R01AI140303 - New Patient-centered Metric for Transplant Center Report Cards
University of Texas Med Br Galveston
FY2024$391,155R01HS028829
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”